Becton, Dickinson and Company (NYSE:BDX) Releases Earnings Results, Beats Estimates By $0.08 EPS

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings data on Thursday. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.08, FiscalAI reports. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.96 EPS.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For fiscal 2026, revenue increased 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70.
• Executives cited broad momentum in growth platforms, including Advanced Patient Monitoring, PureWick, biologic drug delivery, advanced tissue regeneration, and Rowa pharmacy automation. They also highlighted share gains in Alaris and strong adoption of the Incada AI platform, while noting these results reflect targeted commercial and capacity investments.
• Fiscal 2027 guidance calls for low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with operating margins roughly flat. Excluding an estimated 200-basis-point Alaris comparison headwind, revenue growth is expected to be mid-single-digit at the midpoint; Q1 growth is expected at the low end of the annual range.
• Full-year free cash flow rose 42% to $2.9 billion, and conversion improved to approximately 74%, including separation costs; BD expects another meaningful step-up in fiscal 2027. The company returned $3.6 billion to shareholders and said its capital allocation priorities include buybacks, debt reduction, and focused tuck-in acquisitions.
• BD agreed to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion; management said this is a reprioritization of planned investment, not incremental spending. Potential relief from future Section 232 tariffs is not included in guidance and depends on final rules and the company meeting agreed milestones.

Becton, Dickinson and Company Stock Performance

Shares of BDX traded down $1.28 during mid-day trading on Friday, hitting $212.27. The company’s stock had a trading volume of 2,172,550 shares, compared to its average volume of 1,599,485. The stock’s 50-day moving average is $188.17 and its two-hundred day moving average is $170.28. The firm has a market capitalization of $58.49 billion, a PE ratio of 51.27, a price-to-earnings-growth ratio of 13.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $137.35 and a one year high of $214.88.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a $1.06 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of analyst reports. UBS Group started coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. Bank of America increased their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday. Finally, Royal Bank Of Canada upped their price objective on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the stock a “sector perform” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average price target of $193.67.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Share repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.